ArticleJournal, genetic engineering & biotechnology2025
Expression and interaction of RNA binding protein HuR with multidrug transporters (P-GP, MRP1, and ABCG2) in chemoresistant breast and colorectal cancer cells.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multifunctional chitosan-doxorubicin nanocarriers: advancing targeted breast cancer chemotherapy.Molecular cancer · 2026Review
- 7-Ketocholesterol Links Sterol Homeostasis to Hedgehog Signaling and Stress-Survival Responses in MSCs from Patients with Acute Myeloid Leukemia.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemoresistance poses a significant challenge in cancer treatment. Over expression of efflux pumps is one of the primary mechanisms that confer chemoresistance. P-GP, MRP1, and ABCG2, which are important ABC efflux pumps, collectively facilitate the transportation of a wide range of chemotherapeutic drugs out of cells. HuR is known to regulate the expression of various oncogenes through several ways, such as enhancing mRNA trafficking, facilitating mRNA stabilization, and protein translation. This study aimed to investigate the expression pattern of HuR as well as the co-expression pattern of ABC transporters (P-GP, MRP1, and ABCG2) with HuR in chemoresistant breast and colorectal cancer tissues to gain insights into the mechanisms of chemoresistance.
methodsImmunofluorescence imaging as well as bioinformatic tools were used in this study to understand the expression and co-expression patterns of HuR protein and P-GP, MRP1, and ABCG2 in paired case-control chemoresistant samples.
resultsA substantial difference was observed in the level of HuR expression between chemoresistant and control tissues obtained from breast and colorectal cancer patients. The mean relative HuR expression in breast and colorectal chemoresistant tissues was 19.2 and 5.29 times greater, respectively, compared to control tissues. Linear regression analysis revealed that the expression of the ABC efflux transporters (P-GP, MRP1, and ABCG2) is proportional to HuR protein expression in chemoresistant breast and colorectal cancer tissues. Molecular docking analyses between RNA recognition motif (RRM) of the HuR protein and AU-rich elements (ARE) from the 3'UTR of P-GP, MRP1, and ABCG2 mRNA suggested stable binding of HuR to the 3'UTR of the three ABC transporters.
conclusionThe observed overexpression of HuR in chemoresistant tissues suggests its association with chemoresistance mechanisms. Besides, HuR might facilitate posttranscriptional mRNA stabilization of P-GP, MRP1, and ABCG2, which makes it a potential therapeutic target to improve treatment outcomes in chemoresistant patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.